Isocitrate dehydrogenase (IDH) is emphasized as a key biomarker for glioma prediction and prognosis in the 2016 update of the WHO diagnostic criteria (4), and the overall survival (OS) of patients with IDH mutants is significantly better than the OS of those with wild-type IDH (5). Here, IDH3A is linked to central nervous system cancer.